AAAAAA

   
Results: 1-16 |
Results: 16
A PHASE-III RANDOMIZED STUDY COMPARING, IN NON METASTATIC UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC) RESPONDING TO CHEMOTHERAPY (CT), FURTHER CT TO LOCO-REGIONAL IRRADIATION (RT)
Authors: SCULIER JP PAESMANS M BUREAU G RECLOUX P BAUMOHL J VANCUTSEM O BERCHIER MC THIRIAUX J LAFITTE JJ MOMMEN P VANHOUTTE P NINANE V KLASTERSKY J
Citation: Jp. Sculier et al., A PHASE-III RANDOMIZED STUDY COMPARING, IN NON METASTATIC UNRESECTABLE NONSMALL CELL LUNG-CANCER (NSCLC) RESPONDING TO CHEMOTHERAPY (CT), FURTHER CT TO LOCO-REGIONAL IRRADIATION (RT), Annals of oncology, 9, 1998, pp. 399-399
IS CHEMOSENSITIVITY A PREDICTIVE FACTOR FOR RADIOSENSITIVITY IN NONSMALL CELL LUNG-CANCER - LESSON FROM EUROPEAN LUNG-CANCER WORKING PARTY PHASE-III RANDOMIZED TRAIL
Authors: BAUMOHL J SCULIER JP PAESMANS M BUREAU G RECLOUX P VANCUTSEM O BERCHIER MC THIRIAUX J LAFITTE JJ MOMMEN P VANHOUTTE P NINANE V KLASTERSKY J
Citation: J. Baumohl et al., IS CHEMOSENSITIVITY A PREDICTIVE FACTOR FOR RADIOSENSITIVITY IN NONSMALL CELL LUNG-CANCER - LESSON FROM EUROPEAN LUNG-CANCER WORKING PARTY PHASE-III RANDOMIZED TRAIL, Annals of oncology, 9, 1998, pp. 402-402
PHASE-III RANDOMIZED TRIAL COMPARING CISPLATIN AND CARBOPLATIN WITH OR WITHOUT IFOSFAMIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: SCULIER JP PAESMANS M THIRIAUX J LECOMTE J BUREAU G GINER V EFREMIDIS A LAFITTE JJ BERCHIER MC ALEXOPOULOS CG ZACHARIAS C MOMMEN P NINANE V KLASTERSKY J
Citation: Jp. Sculier et al., PHASE-III RANDOMIZED TRIAL COMPARING CISPLATIN AND CARBOPLATIN WITH OR WITHOUT IFOSFAMIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1388-1396
RESPONSE TO CHEMOTHERAPY HAS PREDICTIVE VALUE FOR FURTHER SURVIVAL OFPATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - 10 YEARS EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: PAESMANS M SCULIER JP LIBERT P BUREAU G DABOUIS G THIRIAUX J MICHEL J VANCUTSEM O SERGYSELS R MOMMEN P KLASTERSKY J
Citation: M. Paesmans et al., RESPONSE TO CHEMOTHERAPY HAS PREDICTIVE VALUE FOR FURTHER SURVIVAL OFPATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - 10 YEARS EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY, European journal of cancer, 33(14), 1997, pp. 2326-2332
THE PROGNOSTIC FACTORS FOR ADVANCED NONSM ALL CELL LUNG-CANCER - THE EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: SCULIER JP PAESMANS M LIBERT P BUREAU G DABOUIS G THIRIAUX J MICHEL J VANCUTSEM O SCHMERBER J GINER V BERCHIER MC MOMMEN P SERGYSELS R KLASTERSKY J
Citation: Jp. Sculier et al., THE PROGNOSTIC FACTORS FOR ADVANCED NONSM ALL CELL LUNG-CANCER - THE EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY, Revue des maladies respiratoires, 14(6), 1997, pp. 445-449
A PHASE-II STUDY TESTING A COMBINATION CHEMOTHERAPY WITH EPIRUBICIN AND VINDESINE AS 2ND LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: SCULIER JP BUREAU G THIRIAUX J LECOMTE J RECLOUX P BERCHIER MC KROLL F BROHEE D MOMMEN P PAESMANS M SERGYSELS R KLASTERSKY J
Citation: Jp. Sculier et al., A PHASE-II STUDY TESTING A COMBINATION CHEMOTHERAPY WITH EPIRUBICIN AND VINDESINE AS 2ND LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, International journal of oncology, 7(5), 1995, pp. 1175-1178
A PHASE-II STUDY TESTING WEEKLY PLATINUM DERIVATIVE COMBINATION CHEMOTHERAPY AS 2ND-LINE TREATMENT IN PATIENTS WITH ADVANCED SMALL-CELL LUNG-CANCER
Authors: SCULIER JP THIRIAUX J BUREAU G LAFITTE JJ RECLOUX P BROHEE D BERCHIER MC SERGYSELS R MOMMEN P PAESMANS M KLASTERSKY J LECOMTE J VANSCHAARDENBURG C RICHARD V DIANA D FORTIN F TAGNON A KUSTNER U
Citation: Jp. Sculier et al., A PHASE-II STUDY TESTING WEEKLY PLATINUM DERIVATIVE COMBINATION CHEMOTHERAPY AS 2ND-LINE TREATMENT IN PATIENTS WITH ADVANCED SMALL-CELL LUNG-CANCER, International journal of oncology, 6(2), 1995, pp. 425-429
MAINTENANCE CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER AFTER INDUCTION CHEMOTHERAPY WITH IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN -RANDOMIZED TRIAL CONDUCTED BY THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: SCULIER JP BUREAU G GINER V THIRIAUX J MOMMEN P PAESMANS M KLASTERSKY J
Citation: Jp. Sculier et al., MAINTENANCE CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER AFTER INDUCTION CHEMOTHERAPY WITH IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN -RANDOMIZED TRIAL CONDUCTED BY THE EUROPEAN LUNG-CANCER WORKING PARTY, European journal of cancer, 31A, 1995, pp. 81-81
DELIVERED DOSE INTENSITY WITH AN INDUCTION CHEMOTHERAPY (CT) BY IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN FOR PATIENTS (PTS) WITH SMALL-CELL LUNG-CANCER (SCLC) - A REPORT BY THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: PAESMANS M SCULIER JP BUREAU G GINER V THIRIAUX J MOMMEN P KLASTERSKY J
Citation: M. Paesmans et al., DELIVERED DOSE INTENSITY WITH AN INDUCTION CHEMOTHERAPY (CT) BY IFOSFAMIDE, ETOPOSIDE AND ANTHRACYCLIN FOR PATIENTS (PTS) WITH SMALL-CELL LUNG-CANCER (SCLC) - A REPORT BY THE EUROPEAN LUNG-CANCER WORKING PARTY, European journal of cancer, 31A, 1995, pp. 91-91
PROGNOSTIC FACTORS FOR SURVIVAL IN ADVANCED NON-SMALL-CELL LUNG-CANCER - UNIVARIATE AND MULTIVARIATE ANALYSES INCLUDING RECURSIVE PARTITIONING AND AMALGAMATION ALGORITHMS IN 1,052 PATIENTS
Authors: PAESMANS M SCULIER JP LIBERT P BUREAU G DABOUIS G THIRIAUX J MICHEL J VANCUTSEM O SERGYSELS R MOMMEN P KLASTERSKY J
Citation: M. Paesmans et al., PROGNOSTIC FACTORS FOR SURVIVAL IN ADVANCED NON-SMALL-CELL LUNG-CANCER - UNIVARIATE AND MULTIVARIATE ANALYSES INCLUDING RECURSIVE PARTITIONING AND AMALGAMATION ALGORITHMS IN 1,052 PATIENTS, Journal of clinical oncology, 13(5), 1995, pp. 1221-1230
INDUCTION CHEMOTHERAPY WITH IFOSFAMIDE, ETOPOSIDE, AND ANTHRACYCLINE FOR SMALL-CELL LUNG-CANCER - EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY
Authors: SCULIER JP BUREAU G GINER V THIRIAUX J MICHEL J BERCHIER MC VANCUTSEM O KUSTNER U KROLL F MOMMEN P PAESMANS M KLASTERSKY J
Citation: Jp. Sculier et al., INDUCTION CHEMOTHERAPY WITH IFOSFAMIDE, ETOPOSIDE, AND ANTHRACYCLINE FOR SMALL-CELL LUNG-CANCER - EXPERIENCE OF THE EUROPEAN LUNG-CANCER WORKING PARTY, Seminars in oncology, 22(1), 1995, pp. 18-22
ALLERGY TO LATEX AND PAPAIN
Authors: QUARRE JP LECOMTE J LAUWERS D GILBERT P THIRIAUX J
Citation: Jp. Quarre et al., ALLERGY TO LATEX AND PAPAIN, Journal of allergy and clinical immunology, 95(4), 1995, pp. 922-922
LONG-TERM SURVIVAL AFTER CHEMOTHERAPY CONTAINING PLATINUM DERIVATIVESIN PATIENTS WITH ADVANCED UNRESECTABLE NONSMALL CELL LUNG-CANCER
Authors: SCULIER JP PAESMANS M LIBERT P BUREAU G DABOUIS G THIRIAUX J MICHEL J VANCUTSEM O SCHMERBER J GINER V BERCHIER MC SERGYSELS R MOMMEN P KLASTERSKY J
Citation: Jp. Sculier et al., LONG-TERM SURVIVAL AFTER CHEMOTHERAPY CONTAINING PLATINUM DERIVATIVESIN PATIENTS WITH ADVANCED UNRESECTABLE NONSMALL CELL LUNG-CANCER, European journal of cancer, 30A(9), 1994, pp. 1342-1347
A 4-DRUG COMBINATION CHEMOTHERAPY WITH CISPLATIN, MITOMYCIN, VINDESINE AND 5-FLUOROURACIL - A REGIMEN ASSOCIATED WITH MAJOR TOXICITY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER
Authors: KLASTERSKY J SCULIER JP RIES F DABOUIS G LIBERT P SCHMERBER J THIRIAUX J BERCHIER MC BUREAU G VANCUTSEM O TAGNON A SERGYSELS R MOMMEN P PAESMANS M
Citation: J. Klastersky et al., A 4-DRUG COMBINATION CHEMOTHERAPY WITH CISPLATIN, MITOMYCIN, VINDESINE AND 5-FLUOROURACIL - A REGIMEN ASSOCIATED WITH MAJOR TOXICITY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER, Annals of oncology, 5(7), 1994, pp. 641-643
PHASE-II RANDOMIZED TRIAL COMPARING HIGH-DOSE CISPLATIN WITH MODERATE-DOSE CISPLATIN AND CARBOPLATIN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: SCULIER JP KLASTERSKY J GINER V BUREAU G THIRIAUX J DABOUIS G EFREMIDIS A RIES F BERCHIER MC SERGYSELS R MOMMEN P PAESMANS M
Citation: Jp. Sculier et al., PHASE-II RANDOMIZED TRIAL COMPARING HIGH-DOSE CISPLATIN WITH MODERATE-DOSE CISPLATIN AND CARBOPLATIN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 12(2), 1994, pp. 353-359
A 4-DRUG COMBINATION CHEMOTHERAPY WITH CISPLATIN, MITOMYCIN, VINDESINE AND 5-FLUOROURACIL - A REGIMEN ASSOCIATED WITH MAJOR TOXICITY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER
Authors: KLASTERSKY J SCULIER JP RIES F DABOUIS G LIBERT P SCHMERBER J THIRIAUX J BERCHIER MC BUREAU G VANCUTSEM O TAGNON A SERGYSELS R MOMMEN P PAESMANS M
Citation: J. Klastersky et al., A 4-DRUG COMBINATION CHEMOTHERAPY WITH CISPLATIN, MITOMYCIN, VINDESINE AND 5-FLUOROURACIL - A REGIMEN ASSOCIATED WITH MAJOR TOXICITY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER, Lung cancer, 11(5-6), 1994, pp. 373-384
Risultati: 1-16 |